AIDS players stalk MEDI

Biotech investors illustrated once again last week that they have yet to figure out how to assess the drug development process.

In surging volume of more than 1.3 million shares, the market clipped $1 off MedImmune shares in reaction to AIDS-related news, ignoring two positive revenue-related developments.